$3.35
0.0%
Downside
Day's Volatility :5.9%
Upside
5.9%
0.0%
Downside
52 Weeks Volatility :90.46%
Upside
90.46%
Period | Windtree Therapeutics Inc | |
---|---|---|
3 Months | -50.14% | |
6 Months | -78.52% | |
1 Year | -87.12% | |
3 Years | -99.86% |
Market Capitalization | 2.1M |
Book Value | $30.23 |
Earnings Per Share (EPS) | 13.31 |
PE Ratio | 0.27 |
PEG Ratio | 0.0 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -33.58% |
Return On Equity TTM | -53.1% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -17.8M |
EBITDA | -17.5M |
Diluted Eps TTM | 13.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.97 |
EPS Estimate Next Year | -0.66 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Downside of 10.45%
Sell
Neutral
Buy
Windtree Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Windtree Therapeutics Inc | -28.21% | -78.52% | -87.12% | -99.86% | -99.94% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.54% | 31.88% | 92.14% | 229.83% |
Novo Nordisk A/s | 8.85% | 36.12% | 71.83% | 234.04% | 457.53% |
Vertex Pharmaceuticals Incorporated | 16.81% | 32.76% | 40.6% | 124.79% | 171.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Windtree Therapeutics Inc | 0.27 | 0.27 | 0.0 | -0.97 | -0.53 | -0.34 | NA | 30.23 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Windtree Therapeutics Inc | Sell | $2.1M | -99.94% | 0.27 | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 229.83% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 457.53% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 171.36% | 29.59 | 39.46% |
Vanguard Group Inc
Virtu Financial LLC
Geode Capital Management, LLC
UBS Group AG
windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.
Organization | Windtree Therapeutics Inc |
Employees | 0 |
CEO | Mr. Craig E. Fraser |
Industry | Biotechnology |
A Spac I Acquisition Corp
$3.35
-4.29%
Keyarch Acquisition Corp
$3.35
-4.29%
Connexa Sports Technologies Inc
$3.35
-4.29%
Us Value Etf
$3.35
-4.29%
First Wave Biopharma Inc
$3.35
-4.29%
Global X Msci Next Emerging
$3.35
-4.29%
Fat Projects Acquisition Corp
$3.35
-4.29%
Goal Acquisitions Corp
$3.35
-4.29%
Capital Link Global Fintech
$3.35
-4.29%